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1. Introduction 
Salmonella enterica serotype typhi is the aetiological agent of typhoid fever, a multisystemic 
disease with protean manifestations and initial lesions in the bowel. Typhoid fever still 
remains a major public health problem in developing countries even in the twenty first 
century (Lin et al., 2000; Otegbayo et al., 2003). This was also the case in America and 
Europe three centuries ago, until measures for sanitary disposal and supply of potable water 
were put in place. Unacceptable morbidity and mortality are still recorded in developing 
countries in spite of availability of several drugs over the years for the treatment of typhoid 
fever. There is enough evidence to show that the prevalence of typhoid fever in any 
community is an index of communal hygiene and effectiveness of sanitary disposal. In 
Nigeria, as in other developing countries of the world, studies have estimated over 33 
million cases and 500,000 deaths due to typhoid fever per year (Institute of Medicine, 1986). 
Otegbayo (2005) enumerated several factors responsible for the failure of public health 
measures to tame the tide of the continuing rise in the incidence, prevalence, morbidity and 
mortality of typhoid fever.  
Salmonellosis is an infection with Salmonella bacteria, often restricted to the gastro-
intestinal tract and is often a self limiting disease. Most individuals infected with Salmonella 
typhimurium experience mild gastrointestinal illness involving diarrhoea, chills, abdominal 
cramps, fever, head and body aches, nausea, and vomiting (Honish, 1999). Infections are 
usually self-limiting, and antimicrobial treatment is not recommended for uncomplicated 
illnesses (Aserkoff and Bennet, 1969; Gill and Hammer, 2001). However, extraintestinal 
infection can occur, particularly in very young, elderly, and immunocompromised patients 
(Angulo and Swerdlow, 1995; Thuluvath and McKendrick, 1998). In these cases, effective 
antimicrobial treatment is essential (Cruchaga et al., 2001). Every year, approximately 40,000 
cases of salmonellosis are reported in the United States. The actual number of infections may 
be thirty or more times greater (CDC, 2006). In many parts of the world, such cases are 
either not documented or because many milder cases are not diagnosed or reported. Cases, 
however, of systemic disease due to Salmonella typhimurium and other salmonellae have 
been reported (Panhot and Agarwal, 1982; Varma et al., 2005). Salmonelloses have been 
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reported to be season dependent and occur more in the winter than summer and often 
referred to as gastroenteritis or diarrheoa. Likewise more cases of diarrhoea caused by 
enterobacteriacea especially E. coli, occurring more during wet season than dry season 
(Olowe et al., 2003). Children are the most likely to get salmonellosis, however the elderly, 
and the immunocompromised are the most likely to have severe infections. It is estimated 
that approximately 600 persons die each year with acute salmonellosis as reported by Centre 
for disease control (CDC, 2006). 
2. Multidrug-resistant (MDR) strains of Salmonella 
Multidrug-resistant (MDR) strains of Salmonella are now encountered frequently and the 
rates of multidrug-resistance have increased considerably in recent years (CDC, 2006). Even 
worse, some variants of Salmonella have developed multidrug-resistance as an integral part 
of the genetic material of the organism, and are therefore likely to retain their drug-resistant 
genes even when antimicrobial drugs are no longer used, a situation where other resistant 
strains would typically lose their resistance (CDC, 2006). Most of the strains of Salmonella 
typhimurium isolated in a study in western part on Nigeria were resistant to drugs like 
streptomycin, amoxicilin, tetracycline, ampicillin, kanamycin and chloramphenicol (Olowe 
et al., 2007). This data is alarming since the isolates were already showing high resistance to 
drugs that are meant as alternate therapy to salmonellosis treatment; especially isolates from 
blood were resistant to the commonly used antibiotics. Drug-resistant Salmonella emerged in 
response to antimicrobial usage in food animals, which has also contributed or resulted in 
major outbreaks of salmonellosis (Olowe et al., 2007). Selective pressure from the use of 
antimicrobials is a major driving force behind the emergence of resistance, but other factors 
also need to be taken into consideration. Four types of species namely S. typhi (55.5%) S. 
paratyphi A (48.1%), S. paratyphi B (25.9%) and S. typhimurium (22.2%) were isolated from 
food samples in Namakkal and the isolates showed multiple drug resistance, and 100 % 
resistant to Vancomycin, Novobiocin, Nitrofurantoin, Ciproflaxacin, and Methicillin 
(Jegadeeshkumar et al., 2010). Jegadeeshkumar et al. (2010) also observed increasing 
resistance for Amoxiclave (92.55 %) and Bacitracin (78.57 %). Akinyemi et al. (2000) reported 
that out of the total blood samples cultured, 101 (15.9%) isolates of Salmonella species were 
isolated of which 68 (67.3%) were S. typhi, 17 (16.8%) and 16 (15.8%) were S. paratyphi A 
and S. arizonae respectively. All the S. typhi and S. paratyphi isolates showed resistance to 
two or more of the 10 of 12 antibiotics tested particularly the 3-first-line antibiotics 
commonly used (chloramphenicol, ampicillin and cotrimoxazole) in the treatment of 
typhoid fever in Nigeria.  
Since the discovery of antibiotics and their uses as chemotherapeutic agents, there was a 
belief in the medical fraternity that this would lead to the eradication of infectious diseases. 
However, diseases and disease agents that were once thought to have been controlled by 
antibiotics are returning in new forms resistant to antibiotic therapies (Levy and Marshall, 
2004). Incidents of epidemics due to such drug resistant microorganisms are now a common 
global problem posing enormous public health concerns (Iwu et al., 1999). The global 
emergence of multi-drug resistant bacterial strains is increasingly limiting the effectiveness 
of current drugs and significantly causing treatment failure of infections (Hancock, 2005). 
Examples include methicillin-resistant staphylococci, pneumococci resistant to penicillin 
and macrolides, vancomycin-resistant enterococci as well as multidrug resistant gram-
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negative organisms (Norrby et al., 2005). As resistance to old antibiotics spreads, the 
development of new antimicrobial agents has to be expedited if the problem is to be 
contained. However, the past record of rapid, widespread and emergence of resistance to 
newly introduced antimicrobial agents indicates that even new families of antimicrobial 
agents will have a short life expectancy (Coates et al., 2002). Confronted with a possible 
shortage of new antimicrobials, there is need to ensure a careful use of our available drugs. 
This has led to calls for controlled use of antibiotics through the reduction of dosage used 
per regime of treatment or by regulating prescriptions in areas such as animal husbandry 
and aquaculture (Hernandez, 2005). While, reduced use could lead to delayed resistance 
development, the emergence of resistant strains is from an evolutionary viewpoint 
inevitable. It becomes imperative therefore that alternative approaches are explored. 
Targeting and blocking resistance processes could be an attractive approach. The presence 
of efflux pumps and multidrug resistance (MDR) proteins in antibiotic resistant organisms 
contribute significantly to the intrinsic and acquired resistance in these pathogens. The 
discovery and development of new compounds that either block or circumvent resistance 
mechanisms could improve the containment, treatment, and eradication of these strains 
(Oluwatuyi et al., 2004).  
3. Problems of antibiotic resistance 
The origin of antibiotic resistance extends much further back in evolutionary terms and 
reflects the attack and counter-attack of complex microbial flora in order to establish 
ecological niches and survive. Early treatment failures with antibiotics did represent a 
significant clinical problem because other classes of agents, with different cellular targets, 
were available. The emergence of multiple resistances is causing major problems in the 
treatment options today. Several factors drove this situation in the 1970s and 1980s, 
including the introduction of extended-spectrum agents and advances in medical 
techniques such as organ transplantation and cancer chemotherapy. The net result has 
been a huge selective pressure in favour of multiply resistant species. Coupled with this, 
there has been a sharp decline in the introduction of agents acting on new cellular targets 
over the last 30 years compared with the 20-year period following World War II. Smith 
(2004) reported that the resistant organisms causing concern among Gram-positive 
organisms at present are methicillin resistant Staphylococcus aureus (MRSA) and coagulase-
negative staphylococci, glycopeptides intermediate sensitivity S. aureus (GISA), 
vancomycin-resistant Enterococcus (VRE) species and penicillin-resistant Streptococcus 
pneumoniae. Concerns among the Gram-negative organisms include multidrug-resistant 
Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter baumannii and 
members of the Enterobacteriaceae with extended-spectrum beta- lactamases.  
When infections become resistant to first choice or first line antimicrobials, treatment has to be 
switched to second-or third-line drugs, which are nearly always expensive (Sibanda and 
Okoh, 2007). In many poor countries in developing nations, the high cost of such replacement 
drugs is not easy to come-by, with the result that some diseases can no longer be treated in 
areas where resistance to first-line drugs is widespread (WHO, 2002). The alarming challenges 
facing physicians and pharmacist now, is the need to develop alternative approaches in 
addition to the search for new antimicrobial compounds (Sibanda and Okoh, 2007). Plants 
might hold a promise for combating the problem of antibiotic resistance.  
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4. Mechanisms of antibiotic resistance in pathogenic bacteria 
Resistance to antimicrobial agents typically occurs as a result of four main mechanisms 
namely enzymatic inactivation of the drug (Davies, 1994), alteration of target sites (Spratt, 
1994), reduced cellular uptake (Smith, 2004) and extrusion by efflux (Nakaido, 1994). It has 
been reported that chemical modifications could be significant in antibiotic resistance, 
though exclusion from the cell of unaltered antibiotic represents the primary means in 
denying the antibiotic access to its targets and this is believed to enhance resistance even in 
cases where modification is the main mechanism (Li et al., 1994b). 
4.1 Alteration of target site 
Chemical modifications in the antibiotic target may result in reduced affinity of the 
antibiotic to its binding site (Lambert, 2005). These mechanisms have been reported to be 
employed by a number of pathogenic bacteria in over-powering the effect of antibiotics and 
are usually mediated by constitutive and inducible enzymes. Resistance to macrolides, 
lincosamide and streptogramin B antibiotics (MLSB resistance) in pathogenic Streptococcus 
species is a result of methylation of the N6 amino group of an adenine residue in 23S rRNA. 
This is presumed to cause conformational changes in the ribosome leading to reduced 
binding affinity of these antibiotics to their binding sites in the 50S ribosomal subunit 
(Seppala et al., 1998; Kataja et al., 1998). Beta-lactams antibiotics function by binding to and 
inhibiting the biosynthetic activity of Penicillin Binding Proteins (PBPs), thereby blocking 
cell wall synthesis. 
4.2 Enzymatic inactivation 
The production of hydrolytic enzymes and group transferases is a strategy employed by a 
number of pathogens in evading the effect of antibiotics (Wright, 2005). Genes that code for 
antibiotic degrading enzymes are often carried on plasmids and other mobile genetic 
elements. The resistance to-lactam antibiotics by both gram negative and gram positive 
bacteria has long been attributed to -lactamases (Frere, 1995). These enzymes confer 
significant antibiotic resistance to their bacterial hosts by hydrolysis of the amide bond of 
the four membered-lactam ring (Wilke et al., 2005). Resistance to aminoglycosides in gram-
negative bacteria is most often mediated by a variety of enzymes that modify the antibiotic 
molecule by acetylation, adenylation or phosphorylation (Over et al., 2001). 
4.3 Antibiotic efflux pump 
It is now widely recognized that constitutive expression of efflux pump proteins encoded 
by house-keeping genes that are widespread in bacterial genomes are largely responsible 
for the phenomenon of intrinsic antibiotic resistance (Lomovskaya and Bostian, 2006). 
Several studies have shown that active efflux can be a mechanism of resistance for almost 
all antibiotics (Li et al., 1994a; Gill et al., 1999; Lin et al., 2002). The majority of the efflux 
systems in bacteria are non-drug-specific proteins that can recognize and pump out a 
broad range of chemically and structurally unrelated compounds from bacteria in an 
energy-dependent manner, without drug alteration or degradation (Kumar and 
Schweizer, 2005). 
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The consequence of this drug extrusion is that, it leads to a reduced intracellular 
concentration of the antimicrobial such that the bacterium can survive under conditions of 
elevated antimicrobial concentration (Marquez, 2005). The MIC of the drug against such 
organisms will be higher than predicted. Multi-drug resistance efflux pumps are 
ubiquitous proteins present in both gram-positive and gram-negative bacteria as either 
chromosomally encoded or plasmid encoded (Akama et al., 2005). Although, such 
proteins are present constitutively in bacteria, the continued presence of the substrate 
induces over-expression (Teran et al., 2003). This increased transcription is responsible for 
the acquired resistance. In gram negatives bacteria, the effect of the efflux pumps in 
combination with the reduced drug uptake due to the double membrane barrier is 
responsible for the high inherent and acquired antibiotic resistance often associated with 
this group of organisms (Lomovskaya and Bostian, 2006). 
The NorA protein which is the best studied chromosomally encoded pump in pathogenic 
gram positive bacteria (Hooper, 2005) has been reported to be present in S. epidermidis but 
appears to be absent in Enterococcus faecalis or in gram-negative organisms, such as E. coli 
and K. pneumoniae (Kaatz et al., 1993). Over expression of the NorA gene in S. aureus confers 
resistance to chloramphenicol and hydrophilic fluoroquinolone antimicrobials (Hooper, 
2005; Kaatz and Seo, 1995; Hooper, 2005 instead of Hooper, 2005; Kaatz and Seo, 1995). 
QacA is a member of the major facilitator super-family of transport proteins, which are 
involved in the uniport, symport, and antiport of a wide range of substances across the cell 
membrane (Mitchell et al., 1998). The QacA multidrug exporter from S. aureus mediates 
resistance to a wide array of monovalent or divalent cationic, lipophilic, antimicrobial 
compounds. QacA provides resistance to these various compounds via a proton motive 
force-dependent antiport mechanism (Brown and Skurray, 2001). 
Baucheron et al. (2004) reported the resistance of Salmonella enteric serovar Typhimurium to 
fluororoquinolones, chloramphenicol-florfenicol and tetracycline is highly dependent on the 
presence of AcrAB-TolC efflux pump. S. enterica includes nontyphoidal Salmonella 
belonging to different serotypes on the basis of the flagellar and somatic antigens, and 
represents one of the most important food-borne pathogens causing gastroenteritis in 
humans (Neidhardt, 1996). Nontyphoidal S. enterica strains are easily passed from animals 
to humans and are thus classified as zoonotic pathogens. They can colonize or infect 
humans as well as a variety of domesticated and wild animals ranging from mammals to 
birds and reptiles. Most infections are related to ingestion of contaminated food products 
rather than person-to-person transmission or direct fecal-oral transmission (Mead et al., 
1999). Several S. enterica isolates are characterized by the presence of host-adapted virulence 
plasmids encoding genes contributing to colonization and resistance to complement killing, 
such as the spvA, spvB and spvC (salmonella plasmid virulence) and the rck (resistance to 
complement killing) genes (Guiney et al., 1994). 
In the last few years, Salmonella shows increasing antimicrobial resistance rates in isolates 
obtained from both food animals and humans. S. enterica strains belonging to different 
serotypes and showing multiple antibiotic resistance (to four or more antimicrobials) are 
now widespread in both developed and developing countries, most of these strains are 
zoonotic in origin, acquire their resistance in the food-animal host and cause human 
infections through the food chain (Threlfall, 2002). Salmonella infections have been 
associated with the ingestion of poultry, meat, milk and dairy products (Bean et al., 1996). 
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Most infections result in self-limiting diarrhea and do not require antimicrobial treatment. 
However, severe life-threatening bacteremias and other deep-seated infections do occur, 
particularly in children and immunocompromised hosts and in these cases an antimicrobial 
therapy is recommended (Blaser and Feldman, 1981). Good drugs for Salmonella infections 
include fluoroquinolones, ampicillin, trimethoprimsulfamethoxazole or third-generation 
cephalosporins. Rising rates of resistance to ampicillin and trimethoprimsulfamethoxazole 
have significantly reduced their efficacy and fluoroquinolones are not approved for the use 
in children. Consequently, extended-spectrum cephalosporins have become the current 
drugs of choice for the treatment for invasive infections in children (Hohmann, 2001). The 
emergence of Salmonella species that are resistant to extended-spectrum cephalosporins 
(Herikstad et al., 1997; Threlfall et al., 1997) is cause of worldwide concern. 
4.4 Importance of plasmids in the dissemination of resistance in S. enterica 
Since the aminoglycoside antibiotic apramycin was licensed for veterinary use in the 1980s, 
resistance to apramycin and the related antibiotic gentamicin, one the most frequently used 
aminoglycoside in human therapy (Sibanda and Okoh, 2007). In the United Kindom, during 
the period 1982-84, the incidence of resistance to apramycin in salmonellas increased from 
0.1% in 1982 to 1.4% in 1984 (Wray et al., 1986). Resistance to both apramycin and 
gentamicin was detected in different Salmonella serotypes, as well in Escherichia coli. In 
particular, the incidence of S. enterica (S.) typhimurium definitive type 204c (DT204c) from 
calves showed a dramatically increase (Wray et al., 1986). In S. typhimurium DT204c the 
gentamicin resistance was specified by three types of plasmids of the I1 incompatibility 
group, which also conferred resistance to apramycin (Threlfall et al., 1986). Most of these 
plasmids produced the enzyme aminoglycoside 3-N-acetyltransferase IV and the resistance 
was transferable by conjugation in most of the strains examined. The increasing incidence of 
the gentamicin-resistant S. typhimurium DT204c was also observed in humans, providing the 
first evidence that the use of apramycin in animal husbandry gave rise to resistance to 
gentamicin, an antimicrobial used for human therapy (Threlfall et al., 1986). 
In the 1990s, the increasing frequency of E. coli and Salmonella with plasmids conferring 
resistance to gentamicin and apramycin was reported in other European countries (Chaslus-
Dancla et al., 1991; Pohl et al., 1993). Gentamicin- and apramycin- resistant strains were 
isolated from both humans and cattle in France and Belgium and six different types of 
replicons were identified (Pohl et al., 1993). During the 1990-1997 alarming reports pointed 
out the rapid development in several countries of resistance to β-lactam antibiotics in 
Salmonella (Threlfall et al., 1997). A survey conducted between 1987 and 1994 in France, 
demonstrated a dramatic increase (from 0 to 42.5%) in the prevalence of β-lactam resistance 
among Salmonella isolates. Several types of β-lactamases were found on plasmids belonging 
to different incompatibility groups Q, P, F and HI (Llanes et al., 1999). 
Resistance to β-lactams in Gram-negative bacteria is mediated predominantly by two major 
types of β- lactamases: the chromosomally-encoded enzymes of the Amber class C (e.g. 
AmpC β-lactamase in Citrobacter, Enterobacter, Serratia spp, Morganella morganii and 
Pseudomonas aeruginosa) or by plasmid-encoded enzymes of the Amber class A, in species 
that do not produce AmpC β-lactamases, such as E. coli, Salmonella spp., and Shigella spp. 
(Bauernfeind et al., 1998a). 
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Extended-spectrum β-lactamase (ESBL), evolved from the blaTEM-1, blaTEM-2, and 
blaSHV-1 genes, extending resistance to new third-generation cephalosporins. During the 
last decade, infections caused by S. enterica carrying ESBLs have been reported, and most of 
the ESBL-producing strains were found to carry plasmids encoding the blaTEM- 1, and 
blaSHV-1 gene derivatives (Hammani et al., 1991; Morosini et al., 1995; Tassios et al., 1997; 
Villa et al., 2000; Mulvey et al., 2003). 
In Southern Italy, during the period 1990 to 1998, several epidemiologically unrelated S. 
enteriditis isolates showing resistance to expanded-spectrum cephalosporins were 
recurrently isolated from ill patients. Most of these strains carried the blaSHV-12 gene 
located on conjugative plasmids (Villa et al., 2002a). Notably, this was the first case of 
acquisition of the blaSHV-12 gene by Salmonella in Italy and worldwide. However, SHV-12-
encoding plasmids were previously encountered in K. pneumoniae isolated from hospitals 
throughout Italy (Laksai et al., 2000; Pagani et al., 2000). Therefore, it is plausible that SHV-
12-encoding plasmids originated from nosocomial bacterial pathogens and were 
horizontally transmitted to S. enteriditis strains.  
In 1999, the spread of a S. typhimurium clone resistant to third generation cephalosporins has 
been reported in Russia, Hungary and Greece. In this case non distinguishable institutional 
and community outbreak of S. typhimurium isolates harboured a transferable plasmid 
containing the blaCTX-M gene (Tassios et al., 1999). The relatedness of resistance plasmids 
harboured by strains of various origins can be demonstrated by incompatibility grouping, 
restriction fragmentation pattern analysis and identification of specific resistance 
determinants located within the plasmids. These analyses may allow a better understanding 
of how resistance plasmids propagate, helping to trace their evolution. 
The S. typhimurium pSEM plasmid has a very similar restriction pattern to that of the K. 
oxytoca plasmid, pACM1. The pSEM plasmid was identified in 1997 in S. typhimurium strains 
isolated from children in Albania (Villa et al., 2000), while pACM1 was isolated from K. 
oxytoca strains responsible of a nosocomial outbreak in the USA (Preston et al., 1997; Preston 
et al., 1999). Both plasmids belonged to the same IncL/M group and conferred resistance to 
expanded-spectrum cephalosporins by the blaSHV-5 gene. Both plasmids carried a class 1 
integron conferring aminoglycoside resistance by the aacA4, aacA1 and aadA1 resistance 
gene cassettes (Villa et al., 2000; Preston et al., 1997). Thus, these plasmids could be members 
of a family of broad-host-range replicons widely spreading among Gram-negative 
pathogens. Other plasmids of the IncL/M group showing similar restriction profiles, and 
carrying the blaSHV-5 gene and a class 1 integron, were previously described in several 
countries in Europe from clinical isolates of P. aeruginosa and K. pneumoniae (de Champs et 
al., 1991; Petit et al., 1990; de Champs et al., 1991; Prodinger et al., 1996; Preston et al., 1997 
instaed of de Champs et al., 1991; Petit et al., 1990; Preston et al., 1997, Prodinger et al., 1996). 
The identification of a family of related plasmids has serious public health implications, 
since it demonstrates that broad-host-range plasmids carrying resistance to clinically 
relevant antibiotics can spread worldwide among bacteria responsible of both nosocomial 
and community-acquired infections. The fact that conserved plasmids can be identified in a 
wide variety of pathogens isolated in different countries, illustrates the important role of 
plasmids in the dissemination of antimicrobial resistance among Gram-negative bacteria. 
Recently, a case of treatment failure due to ceftriaxone resistant S. anatum has been 
reported in Taiwan (Su et al., 2003). In this study, ceftriaxone-susceptible S. anatum was 
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initially isolated from the urine of a 70-year-old diabetic patient hospitalized for the 
treatment of a large pressure sore in the sacral area and urinary tract infection. The 
unexpected emergence of the resistance during the treatment with ceftriaxone led to 
systemic bacteraemia by S. anatum and to the fatal outcome in the patient. The emergence 
of the resistance has been linked to the in vivo acquisition of a resistance plasmid carrying 
the CTX-M3 β-lactamase by the susceptible S. anatum strain. In the same hospital this β-
lactamase has been previously identified in clinical isolates of E. coli, K. pneumoniae and 
Enterobacter cloacae, suggesting that such bacteria may have acted as reservoirs of the 
resistance plasmid (Su et al., 2003). 
4.5 Plasmid-mediated resistance to expanded-spectrum cephalosporins encoded by 
the CMY-2 AmpC β- lactamase 
The ampC genes were regarded as exclusively chromosomal until 1989, when an AmpC-
type β-lactamase was found for the first time on transmissible plasmids (Bauernfeind et 
al., 1998a). Plasmid-mediated AmpC β-lactamases belong to the homogeneous group of 
genes related to the chromosomal ampC gene of Citrobacter freundii (cmy-2, bil-1 and lat 
genes), the cmy-1, fox and mox family, or originate from the Morganella morganii AmpC β-
lactamase (DHA-1) (Bauernfeind et al., 1998a). The latter was identified on a plasmid in S. 
enteriditis (Barnaud et al., 1998; Verdet et al., 2000). The first case of plasmid-mediated 
CMY-2 in Salmonella was reported on a conjugative plasmid of S. senftenberg recovered in 
1994 from stool of an Algerian child (Koeck et al., 1997). Review of 1996 data from the 
National Antimicrobial Resistance Monitoring System (NARMS) in the United States 
identified only 1 (0.1%) Salmonella isolate among 1272 human Salmonella isolates 
showing expanded spectrum cephalosporin resistance (Dunne et al., 2000). However, in 
1999, NARMS reported the emergence of domestically acquired broad-spectrum 
cephalosporin resistant Salmonella, most of them producing the CMY-2 AmpC β-
lactamase (Dunne et al., 2000). 
S. typhimurium strains carrying indistinguishable CMY-2-encoding plasmids were isolated 
in Nebraska from a patient and cattle during a local outbreak of salmonellosis, 
demonstrating that the Salmonella-resistant strain evolved primarily in livestock (Fey et al., 
2000). Since 1998, Salmonella of human and animal origin were reported to show resistance 
to expanded-spectrum cephalosporins, in Iowa (Winokur et al., 2000; Winokur et al., 2001). 
Molecular studies demonstrate the emergence of plasmid encoded CMY-2 β-lactamase in 
most cephalosporin resistant isolates. During the 1998-1999 periods, nearly 16% of E. coli 
isolates and 5.1% of Salmonella isolates from clinically ill animals in Iowa produced CMY-2 
(Winokur et al., 2000; Winokur et al., 2001). 
Similar plasmids, carrying the cmy-2 gene were also reported in Salmonella isolated from 
animals in Illinois (Odeh et al., 2002). The spreading of the CMY-2-carrying plasmids in the 
USA was confirmed by molecular analysis of domestically acquired Salmonella strains of 
human origin isolated in nine different States, representing the 87% of the total expanded-
spectrum cephalosporin resistant Salmonella collected by the Center for Disease Control and 
Prevention (CDC) during the 1996-1998 surveillance periods. The isolates were 
distinguishable by their chromosomal DNA patterns, thus demonstrating that they did not 
represent the epidemic spread of a clonal strain (Dunne et al., 2000). 
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4.6 The use of resistance modifying agents in combination with antibiotics to 
overcome resistance 
The selection pressure exerted by the continued presence of bactericidal or bacteriostatic 
agents facilitates the emergence and dissemination of antibiotic resistance genes. Over 
generations, the genotypic makeup of bacterial populations is altered (Taylor et al., 2002). 
The clinical implications of this are that many infections become untreatable resulting in 
serious morbidity and mortality. Although the introduction of new compounds into clinical 
use has helped to curtail the spread of resistant pathogens, resistance to such new drugs, has 
developed in some cases. It has been observed by several studies that antibiotic 
combinations can have synergistic benefits and interactions between existing antibiotics 
(Bayer et al., 1980; Hallander et al., 1982; Hooton et al., 1984; Cottagnoud et al., 2000; instaed of 
Bayer et al., 1980; Hooton et al., 1984; Cottagnoud et al., 2000; Hallander et al., 1982.). Several 
current therapeutic regimes are based on synergistic interactions between antibiotics with 
different target sites. As new antimicrobial compounds are discovered, there is need to assess 
their potentials in combination therapies with old antibiotics that have been rendered 
ineffective by the development of resistant strains, even when such compounds are not 
directly evidently inhibitory. Taylor et al. (2002) suggested that the use of agents that do not 
kill pathogenic bacteria but modify them to produce a phenotype that is susceptible to the 
antibiotic could be an alternative approach to the treatment of infectious disease. Such agents 
could render the pathogen susceptible to a previously ineffective antibiotic, and because the 
modifying agent applies little or no direct selective pressure, this concept could slow down or 
prevent the emergence of resistant genotypes. The inhibition of resistance expression approach 
was successfully used in the production of Augmentin, a combination of amoxycillin and 
clavulanic acid (Reading and Cole, 1977). In this case, clavulanic acid is an inhibitor of class-A-
lactamases which is coadministered with amoxicillin. The combination has been used clinically 
since the late 1970s (Neu et al., 1993). A similar approach can be used for target-modifying 
enzymes and for efflux systems. A number of in vitro studies have reported the use of plant 
extracts in combination with antibiotics, with significant reduction in the MICs of the 
antibiotics against some resistant strains (Al-hebshi et al., 2006; Darwish et al., 2002; Al-hebshi 
et al., 2006; Betoni et al., 2006 instead of Al-hebshi et al., 2006; Darwish et al., 2002; Betoni et al., 
2006). The curative effect of plant extracts in this combination study has been variably referred 
to as resistance modifying/modulating activity (Gibbons, 2004). This ability of plant extracts to 
potentiate antibiotics has not been well explained. It is speculated that inhibition of drug 
efflux, and alternative mechanisms of action could be responsible for the synergistic 
interactions between plant extracts and antibiotics (Lewis and Ausubel, 2006; Zhao et al., 2001; 
Lewis and Ausubel, 2006; instead of Lewis and Ausubel, 2006; Zhao et al., 2001). 
4.7 Efflux pump inhibition in combination with antibiotics as a strategy for 
overcoming resistance 
The discovery and development of clinically useful Efflux Pump Inhibitors (EPIs) that 
decrease the effectiveness of efflux pumps represents a significant advance in the 
development of therapeutic regimes for the treatment of MDR-related conditions. This 
approach termed the EPI strategy (Lomovskaya and Bostian, 2006), is based on blocking the 
activity of the pumps, resulting in the accumulation of the antibiotic inside the bacterial cell, 
consequently increasing access to its target sites. In addition, this will lead to increased 
susceptibility of the bacterium, thus implying that the therapeutic effect of the drug is 
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achieved with low concentrations. Combining broad spectrum efflux pump inhibitors with 
current drugs that are pump substrates can recover clinically relevant activity of those 
compounds and thus may provide new dimensions to the ever increasing need for 
development of new antimicrobial agents. This approach will in addition lead to the 
preservation and improvement of the usefulness of old and cheap antibacterial agents. 
Ultimately this could reduce the appearance and spread of resistant mutants (Kaatz, 2002). 
4.8 Role of Ethnopharmacology in the treatment of Salmonellosis 
Herbal medicine is used globally and has a rapidly growing economic importance. In 
developing countries, traditional medicine is often the only accessible and affordable 
treatment available. In Africa, 80% of the population uses traditional medicine as the 
primary health care system (Fisher and Ward, 1994). Traditional medicine is also gaining 
more respect by national governments and health providers. Peru’s national program in 
complementary medicine and the Pan American health organization recently compared 
complementary medicine in clinics and hospitals within the Peruvian social security system 
(Lima, 2000). Plants have been used in traditional medicine for several thousand years (Abu 
– Rabia, 2005). The knowledge of medicinal plants has been accumulated in the course of 
many centuries based on different medicinal system. During the last few decades there is an 
increasing interest in the study of medicinal plants and their traditional use in different 
parts of the world (Rossato et al., 1999). There are considerable economic benefits in the use 
of medicinal plants for the treatments of various diseases (Azaizeh, 2003). Due to less 
communication means, poverty, ignorance and unavailability of modern health facilities, 
most of the rural people are forced to practice traditional medicines for their common day 
ailments. Most of these people form the poorest link in the trade of medicinal plants (Khan, 
2002). A vast knowledge of how to use the plants against different illness may be expected 
to have accumulated in areas were the use of plants is still of great importance (Diallo et al., 
1999). In the developed countries, 25% of the medical drugs are based on plants and their 
derivatives (Principe, 1991). A group of World Health Organization experts, who met in 
Congo, Brazzaville in 1976, sought to define traditional African medicine as the sum total of 
practices, measures, ingredients and procedures of all kinds whether material or not, which 
from time immemorial has enabled the African to guard against diseases to alleviate his / 
her suffering and cure him / herself (Busia, 2005). Traditional medical knowledge of 
medicinal plants and their use by indigenous cultures are not only useful for conservation of 
community health care and biodiversity but also for community health care and drug 
development in the present and future (Pei, 2001).  
A number of workers have evaluated the anti typhoidal activities of medicinal plants and 
some of them proved to be promising. For example: Aliero and Wara (2009) evaluated the 
efficacy of Leptadenia hastata (Pers.) Decne extracts against five selected bacterial species and 
two fungal species. Aqueous extract markedly inhibited the growth of Salmonella paratyphi 
and Escherichia coli and Pseudomonas aeruginosa. The result obtained in this study has 
provided a scientific support for the claimed ethnomedical uses of aqueous extracts of L. 
hastata in the treatment of bacterial diseases and suggest the potential of methanol extract as 
a source of antifungal agent. Evans et al. (2002) evaluated the efficacy of Euphobia hirta; 
Citrus aurantifolia, Cassia occidentalis, and Cassia eucalyptus claimed by the Nupes tribe of 
Nigeria to be effective in the treatment of typhoid fever. The result of invitro antimicrobial 
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analysis showed that, only Cassia eucalyptus showed inhibition of Salmonella typhi growth 
and concluded that the plant is efficacious and contains natural compounds that could be 
used in the treatment of typoid fever. Similarly, In Camerron, Nkuo-Akenji et al. (2001) 
evaluated the effects of herbal extracts derived from plants commonly prescribed by 
traditional practitioners for the treatment of typhoid fever against Salmonella typhi, S. 
paratyphi and S. typhimurium using formulations often prescribed by the traditional healers 
which includes; 1) Formulation A comprising Cymbogogon citratus leaves, Carica papaya 
leaves, and Zea mays silk. 2) Formulation B comprising C. papaya roots, Mangifera indica 
leaves, Citrus limon fruit and C. citratus leaves. 3) C. papaya leaves. 4) Emilia coccinea whole 
plant. 5) Comelina bengalensis leaves. 6) Telfaria occidentalis leaves. 7) Gossypium arboreum 
whole plant. The result obtained in this study, showed that Formulation A elicited 
inhibitory activity at a lower range of 0.02 to 0.06 mg/ml. Similarly, Formulation B elicited 
bacterial activity at the lowest range of 0.06 to 0.25mg/ml. C. bengalensis leaves on the other 
hand, showed the lowest activity with a concentration range of 0.132 to 2.0 mg/ml and 1 to 
4 mg/ml in MIC and MBC assays respectively. The result demonstrated that S. paratyphi 
was most sensitive to the formulations (concentration range of 0.02 to 1 mg/ml in both MIC 
and MBC assays) while S. typhimurium was the least sensitive and concentrations of up to 4 
mg/ml were required to be bactericidal.  
Iroha et al. (2010) evaluated the anti Salmonella typhi activity of ethanol, hot and cold crude 
water extracts of Vitex doniana (root), Cassia tora (Leaf), Alstonia boonei (bark), Stachytarpheta 
jamaicensis (leaf), and Carica papaya (leaf) used as traditionally medicine in Ebonyi state, 
Nigeria. Ethanol extracts of Vitex doniana exhibited anti-typhoid activity against 9(90%) of 
the test organisms, A. boonei exhibited activity against 8(80%) of the test organisms, C. papaya 
against 2(20%), C. tora against 6(60%), and S. jamaicensis against 6(60%). Hot water extract of 
Vitex doniana showed anti-typhoid activity against 7(70%) of the test organisms, A. boonei 
against 9(90%), C. papaya against 1(10%), C. tora against 8(80%) and S. jamaicensis against 
7(70%). Cold water extract of V. doniana, had anti-typhoid activity against 6(60%) of the test 
organisms, A. boonei, against 6(60%), C. papaya against 0(0%), C. tora against 6(60%) and S. 
jamaicensis against 4(40%). MIC of ethanol, hot and cold water extracts of V. doniana, A. 
boonei, C. papaya, C. tora and S. jamaicensis, fall within 0.4 -128, 0.8 -128, 64 -128, 32 – 128 and 
32 – 128. MIC of hot water extracts were within 16 -128, 0.8 – 128, 128 -512, 0.8 – 512 and 0.8 
– 128 while MIC of cold water extract are within 64 – 128, 64 – 512, 64 – 512, 64 – 512 and 
128-512 respectively. The results of these findings showed that ethanol and hot water 
extracts of V. doniana and A. boonei had the best antityphoid activity.  
The work of Oluduro and Omoboye (2010) investigated the antibacterial potency and 
synergistic effect of crude aqueous and methanolic extracts of nine plant parts against multi-
drug resistant S. typhi tested against nine plant parts: unripe Carica papaya fruit, Citrus 
aurantifoliia, Anana sativus, Citrus paradisi, Cymbopogon citratus, Cocos nucifera leaves of Carica 
papaya, leaves of Euphorbia heterophylla and Gossypium spp. Both the aqueous and methanol 
extracts of each plant material and mixture showed appreciable antimicrobial activities on S. 
typhi. Antimicrobial activity increased with increasing concentration of the extracts. 
Synergistic activity of crude aqueous and crude methanolic extracts of the plant parts, in 
various combinations of two to nine against the test organism ranged from 10-33 mm zone 
of growth inhibition. The antibacterial efficacy of the mixture of extracts from plant parts 
increased considerably compared to the low activities recorded with the extract of 
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individual plant parts (P>0.05). Methanolic extracts of each plant material and mixture 
produced greater antimicrobial activity than the aqueous extracts at all concentrations. The 
minimum inhibitory concentration (MIC) of the individual plant parts ranged between 0.1 and 
1.0 mg/ml in aqueous extracts and 0.01 and 0.1 mg/ml in methanol extracts while the MICs of 
the combined extracts ranged between 0.1 and 0.01 mg/ml in aqueous extracts and 0.01 and 
0.0001 mg/ml in methanolic extracts. The combined or synergistic activity of the plant parts 
compared favourably with the standard antibiotics of choice for salmonella-infections therapy, 
and contained two or more phytochemicals responsible for their antimicrobial activities. There 
is the need therefore to develop effective combination of antimicrobial agents in purified 
form from higher plants and their parts for clinical trials. Frey and Meyers (2010) reported 
that Achillea millefolium, Ipomoea pandurata, Hieracium pilosella, and Solidago canadensis 
exhibited antimicrobial properties as expected, with particularly strong effectiveness against 
S. typhimurium. In addition, extracts from Hesperis matronalis and Rosa multiflora also 
exhibited effectiveness against this pathogen. 
4.9 Plants as sources of new antimicrobials and resistance modifying agents 
Plants have traditionally provided a source of hope for novel drug compounds, as plant 
herbal mixtures have made large contributions to human health and well-being (Iwu et al., 
1999). Owing to their popular use as remedies for many infectious diseases, searches for 
substances with antimicrobial activity in plants are frequent (Shibata et al., 2005; Betoni et 
al., 2006). Plants are rich in a wide variety of secondary metabolites, such as tannins, 
terpenoids, alkaloids, and flavonoids, which have been found in vitro to have antimicrobial 
properties (Cowan, 1999; Lewis and Ausubel, 2006). Examples of some of these compounds 
are shown in Table 1. Literature is awash with compounds that have been isolated from a 
variety of medicinal plants. Despite this abundant literature on the antimicrobial properties 
of plant extracts, none of the plant derived chemicals have successfully been exploited for 
clinical use as antibiotics (Gibbons, 2004). A significant part of the chemical diversity 
produced by plants is thought to protect plants against microbial pathogens. Gibbons (2004) 
reported that a number of plant compounds often classified as antimicrobial produce MIC 
greater than 1,000 μg/ml, which are of no relevance from a clinical perspective. Tegos et al. 
(2002) suggested that a vast majority of plant compounds showing little in vitro antibacterial 
activity are not antimicrobial but are regulatory compounds playing an indirect role in the 
plant defence against microbial infections. The observation that plant derived compounds 
are generally weak compared to bacterial or fungal produced antibiotics and that these 
compounds often show considerable activity against gram-positive bacteria than gram-
negative species has been made by many (Nostro et al., 2000; Gibbons, 2004). This 
observations led Tegos et al. (2002) hypothesizing that; Plants produce compounds that can 
be effective antimicrobials if they find their way into the cell of the pathogen especially 
across the double membrane barrier of Gram negative bacteria. Production of efflux pump 
inhibitors by the plant would be one way to ensure delivery of the antimicrobial compound. 
This hypothesis has been supported by the findings of Stermitz et al. (2000 a,b), who 
observed that Berberis plants which produce the antimicrobial compound, berberine, also 
make the MDR inhibitors 5-methoxyhydnocarpin D (5-MHC-D) and pheophorbide A. The 
MDR inhibitors facilitated the penetration of berberine into a model gram-positive 
bacterium, S. aureus. In testing their hypothesis, Tegos et al. (2002), showed that two MDR 
inhibitors (INF271 and MC207110) dramatically increased the effectiveness of thirteen 
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putative plant antimicrobial compounds against gram-negative and gram positive bacteria 
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Table 1. Examples of some plants with active antimicrobial derived compounds. 
These studies have provided the bases for understanding the action of plant antimicrobials, 
namely that vast majority of such compounds are agents with weak or narrow-spectrum 
activities that act in synergy with intrinsically produced efflux pump inhibitors. There is 
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reason therefore to believe that, plants could be a source of compounds that can increase the 
sensitivity of bacterial cells to antibiotics. Such compounds could be useful particularly 
against antibiotic resistant strains of pathogenic bacteria. The rich chemical diversity in 
plants promises to be a potential source of antibiotic resistance modifying compounds and 
has yet to be adequately explored. 
4.10 Resistance modifying activities of plants crude extracts: The basis for isolation 
of potentially useful compounds 
If the isolation of resistance modifying compounds from plants is to be realistic, screening 
for such activities in crude extracts is the first step in identifying leads for isolation of such 
compounds, and some plants have provided good indications of these potentials for use in 
combination with antimicrobial therapy. Typical examples are as follows: Aqueous extracts 
of tea (Camellia sinensis) have been shown to reverse methicillin resistance in MRSA and 
also, to some extent, penicillin resistance in beta lactamase-producing Staphylococcus aureus 
(Stapleton et al., 2004). Forty to one hundred fold dilutions of tea extracts was able to reduce 
the MICs of high- level resistant MRSA (256 μg/ml) to less than 0.12 μg/ml for methicillin 
and penicillin (Yam et al., 1998; Stapleton et al., 2004). Aqueous crude khat (Catha edulis) 
extracts of Yemen showed varying antibacterial activities with a range of 5-20 mg/ml-1 
against periodontal bacteria when tested in isolation. Addition of the extracts at a sub- MIC 
(5 mg/ml) resulted in a 2 to 4-folds potentiation of tetracycline against resistant strains 
Streptococcus sanguis TH-13, Streptococcus oralis SH-2, and Fusobacterium nucleatum (Al-hebshi 
et al., 2006). Betoni et al. (2006), observed synergistic interactions between extracts of guaco 
(Mikania glomerata), guava (Psidium guajava), clove (Syzygium aromaticum), garlic (Allium 
sativum), lemongrass (Cymbopogon citratus), ginger (Zingiber officinale), carqueja (Baccharis 
trimera), and mint (Mentha pieria) from Brazil and some antibiotics which represented 
inhibitors of protein synthesis, cell wall synthesis, nucleic acid synthesis and folic acid 
synthesis against Staphylococcus aureus. Darwish et al. (2002) reported that sub-inhibitory 
levels (200 μgml−1) of methanolic extracts of some Jordanian plants showed synergistic 
interactions in combination with chloramphenicol, gentamicin, erythromycin and penicillin 
G against resistant and sensitive S. aureus. The methanolic extract of Punica granatum 
(PGME) showed synergistic interactions with chloramphenicol, gentamicin, ampicillin, 
tetracycline, and oxacillin. The bactericidal activity of the combination of PGME (0.1×MIC) 
with ampicillin (0.5×MIC) by time-kill assays, reduced cell viability b 99.9 and 72.5% in 
MSSA and MRSA populations, respectively (Braga et al., 2005). The ethanol extracts of the 
Chinese plants, Isatis tinctoria and Scutellaria baicalensis in combination with ciprofloxacin 
had synergistic activities against antibiotic resistant S. aureus (Yang et al., 2005). The 
combinations of pencillin with ethanolic extracts of Paederia scandens and Taraxacun 
monlicum showed a strong bactericidal activity on two strains of S. aureus (Yang et al., 2005). 
When Ciprofloxacin was incorporated at sub-inhibitory concentrations (1/8MIC) to the 
crude chloroform extracts of Jatropha elliptica and the mixture assayed against NorA 
expressing S. aureus, the activity of the extract was enhanced. This suggests the presence of 
an inhibitor of the pump which could restore the activity of Ciprofloxacin (Marquez et al., 
2005). In another study, Ahmad and Aqil (2006) observed that crude extracts of Indian 
medicinal plants, Acorus calamus, Hemidesmus indicus, Holarrhena antidysenterica and 
Plumbago zeylanica showed synergistic interactions with tetracycline and ciprofloxacin 
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against extended Spectrum beta-lactamase (ESBL), producing multidrug-resistant enteric 
bacteria with ciprofloxacin showing more synergy with the extracts than tetracycline. 
4.11 Plant compounds as resistance modifying agents 
Some isolated pure compounds of plant origin have been reported to have resistance 
modifying activities in vitro. Examples of some of the compounds are given in Table 2. This 
has prompted the search for such compounds from a variety of medicinal plants. Some of 
the compounds which have been observed to have direct antimicrobial activity have been  
 

































Oluwatuyi et al. 
(2004) 
Ethyl gallate Caesalpinia spinosa Bate-lactams 



























Gibbons et al. 
(2004) 
Hu et al. (2002) 
Zhao et al. (2001) 
Sibanda and Okoh, 2007 
Table 2. Some antibiotic resistance modifying compounds from plants. 
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shown to be potentiating against the activity of antibiotics when used at low MIC levels. The 
antimicrobial properties of tea (Camellia sinensis) have been found to be a result of the presence 
of polyphenols (Yam et al., 1998; Stapleton et al., 2004; Si et al., 2006). Bioassay directed 
fractionation of the extracts revealed that epicatechin gallate (ECG), epigallocatechin gallate 
(EGCG), epicatechin (EC), and caffeine (CN) are the bioactive components. ECG and CG 
reduced MIC values for oxacillin from 256 and 512 to 1 and 4 mgl-1 against MRSA (Shibata et 
al., 2005). Ethyl gallate, a conginer of alkyl gallates purified from a dried pod of tara 
(Caesalpinia spinosa) native to South America, intensified lactam susceptibility in MRSA an 
MSSA strains (Shibata et al., 2005). The abietane diterpenes, (carnosic acid carnosol) isolated 
from the aerial parts of Rosmarinus officinalis by fractionation of its chloroform extract at 10 
μgml-1, potentiated the activity of erythromycin (16 - 32 fold) against strains of S. aureus that 
express the two efflux proteins MsrA and TetK. Additionally, carnosic acid was shown to 
inhibit ethidium bromide efflux in a NorA expressing S. aureus strain (Oluwatuyi et al., 2004). 
A penta-substituted pyridine, 2, 6-dimethyl-4-phenylpyridine-3, 5-dicarboxylic acid diethyl 
ester and proparcine have been isolated from an ethanol extract of rhizome of Jatropha elliptica 
by bioassay guided fractionation. The pyridine at a concentration of 75 μgml-1 was shown to 
increase by 4-fold, the activity of ciprofloxacin and norfloxacin against NorA expressing S. 
aureus when tested at sub-inhibitory concentrations (Marquez et al., 2005). Smith et al. (2007) 
screened active compounds from the cones of Chamaecyparis Lawsoniana for resistance 
modifying activities and observed that Ferruginol and 5-Epipisiferol were effective in 
increasing the efficacy of tetracycline, norfloxacin, erythromycin and Oxacillin against resistant 
S. aureus. The majority of researches on the combinations between plant extracts and 
antibiotics have been focused on the identification and isolation of potential resistance 
modifiers from such natural sources which are considered to be positive results. However, it is 
likely that such combinations could produce antagonistic interactions that most studies have 
considered irrelevant and therefore ignored (Sibanda and Okoh, 2007). 
5. Suggested solutions to challenges in management 
There are still loopfuls of challenges in many developing countries for the management of 
typhoid fever. Otegbayo (2005) gave the following suggestions as solution for typhoid fever 
management. This include among others, the improvement in personal and communal 
hygiene, effective waste disposal system and provision of potable water. Effective treatment 
of index cases, health education both for the populace and physicians are other important 
measures. Determination of drug sensitivity patterns and aggressive policy will be quite 
helpful. The difficulty in diagnosis could also be overcome by making laboratory facilities 
such as culture media available. Parry et al. (2002) recently suggested the use of conjugate Vi 
vaccine as part of the Expanded Programme of Immunization. The cost-effectiveness of this 
latter measure may however be negative for resource – poor countries, where preventive 
measures by way of improved sanitation and provision of potable water would be more 
beneficial. Above all, resources should be made available, accessible and affordable to the 
common man; National Health Insurance appears to be the answer to this as well as 
economic empowerment of the people in emerging economies. 
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